Login to Your Account

With FDA's blessing, MDCO set to take PCSK9 into pivotal program

By Marie Powers
News Editor

Wednesday, April 26, 2017

Despite a tepid response from payers to first approvals in the PCSK9 drug class, The Medicines Co. plans to move aggressively into a pivotal phase III program for its candidate, inclisiran.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription